A Phase I Study of MEDI7247 in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma

Full Title

D8540C00001: A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancies

Purpose

The purpose of this study is to determine the highest dose of the investigational drug MEDI7247 that can be given safely in patients with diffuse large B-cell lymphoma that has continued to grow or came back despite prior treatment. MEDI7247 is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have diffuse large B-cell lymphoma that has continued to grow or came back despite prior therapy and cannot be successfully treated using standard therapies.
  • At least 3 weeks must pass since the completion of previous chemotherapy and 4 weeks since any major surgery, immunotherapy, or radiation therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Connie Batlevi at 212-639-8081.

Protocol

18-220

Phase

III

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators